Creative Planning
LAB icon

Creative Planning’s Standard BioTools LAB Stock Holding History

Creative Planning’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$66.1K Buy
80,331
+61,863
+335% +$58.5K ﹤0.01% 4087
2026
Q1 		$17K Sell
18,468
-27,567
-60% -$33.4K ﹤0.01% 4052
2025
Q4 		$58.9K Sell
46,035
-16,961
-27% -$22.8K ﹤0.01% 3789
2025
Q3 		$81.9K Buy
62,996
+1,894
+3% +$2.48K ﹤0.01% 3703
2025
Q2 		$73.3K Buy
61,102
+22,082
+57% +$24.5K ﹤0.01% 3473
2025
Q1 		$42.1K Sell
39,020
-8,258
-17% -$11.6K ﹤0.01% 3358
2024
Q4 		$82.7K Buy
47,278
+26,950
+133% +$50.2K ﹤0.01% 3180
2024
Q3 		$39.2K Buy
+20,328
New +$39.8K ﹤0.01% 3113
2015
Q4 		– Sell
-5,000
Closed -$41K – 4502
2015
Q3 		$41K Buy
+5,000
New +$78.7K ﹤0.01% 2175

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Creative Planning's LAB Position: Q2 2026 in Review

Creative Planning increased its Standard BioTools (LAB) stake by 335% in Q2 2026, buying an estimated $58.5K and bringing the position to 80,331 shares worth $66.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4087.

Creative Planning first reported a position in LAB in Q3 2015 and has held it in 9 quarters since. The position peaked at $82.7K in Q4 2024. 144 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Creative Planning held 80,331 shares of Standard BioTools worth $66.1K as of Q2 2026.
  • Creative Planning bought 61,863 Standard BioTools shares in Q2 2026, an estimated $58.5K.
  • Standard BioTools made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #4087 holding.
  • Creative Planning first reported a position in Standard BioTools in Q3 2015 and has held it in 9 quarters since.
  • Creative Planning's Standard BioTools position peaked at $82.7K in Q4 2024.
  • 144 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.